Acadia Pharmaceuticals Inc. saw its market cap double Monday following positive Phase IIb findings showing that its investigational compound ACP-103 improved the efficacy of a widely prescribed schizophrenia drug and also minimized its side effects. (BioWorld Today)

Acadia Pharmaceuticals Inc. saw its market cap double Monday following positive Phase IIb findings showing that its investigational compound ACP-103 improved the efficacy of a widely prescribed schizophrenia drug and also minimized its side effects. (BioWorld Today)